title: [Economic aspects of inpatient treatment for decompensated liver cirrhosis: a prospective study employing an evidence-based clinical pathway].
abstract: The introduction of the G-DRG reimbursement system has greatly increased the pressure to provide cost effective treatment in German hospitals. Reimbursement based on diagnosis-related groups, which requires stratification of costs incurred is still not sufficiently discriminating the disease severity and severity in relation to the intensive costs in gastroenterology. In a combined retrospective and prospective study at a tertial referral centre we investigated whether this also applies for decompensated liver cirrhosis. In 2006, 64 retrospective cases (age 57 ± 12.9; ♂ 69.2 %, ♀ 29.8 %) with decompensated liver cirrhosis (ICD code K76.4) were evaluated for their length of hospitalisation, reimbursement as well as Child and MELD scores. In 2008, 74 cases with decompensated liver cirrhosis were treated in a prospective study according to a standardised and evidence-based clinical pathway (age 57 ± 12.2; 73 % ♂, ♀ 27 %). Besides a trend in the reduction of length of hospital stay (retrospective: 13.6 ± 8.6, prospective 13.0 ± 7.2, p = 0.85) overall revenues from patients treated according to a evidence-based clinical pathway were lower than the calculated costs from the InEK matrix. Costs of medication as a percentage of reimbursement amount increased with increasing severity. In both years we could demonstrate an inverse correlation between daily reimbursement and disease severity which precluded cost coverage. For the cost-covering hospital treatment of patients with decompensated liver cirrhosis an adjustment of the DRG based on clinical severity scores such as Child-Pugh or MELD is warranted, if evidence-based treatment standards are to be kept.
authors.affiliation: Klinik und Poliklinik für Innere Medizin A, Universitätsmedizin der Ernst-Moritz-Arndt-Universität Greifswald, Greifswald, Germany.
authors.forename: N
authors.initials: N
authors.lastname: Hahn
authors.forename: C
authors.initials: C
authors.lastname: Bobrowski
authors.forename: E
authors.initials: E
authors.lastname: Weber
authors.forename: P
authors.initials: P
authors.lastname: Simon
authors.forename: M
authors.initials: M
authors.lastname: Kraft
authors.forename: A
authors.initials: A
authors.lastname: Aghdassi
authors.forename: M
authors.initials: M
authors.lastname: Raetzell
authors.forename: M
authors.initials: M
authors.lastname: Wilke
authors.forename: M M
authors.initials: MM
authors.lastname: Lerch
authors.forename: J
authors.initials: J
authors.lastname: Mayerle
mesh_terms: D019091:Critical Pathways / Q000191:economics*; D019317:Evidence-Based Medicine / Q000191:economics* / Q000379:methods; D005260:Female; D005858:Germany / Q000453:epidemiology; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006760:Hospitalization / Q000191:economics* / Q000706:statistics & numerical data; D006801:Humans; D007297:Inpatients / Q000706:statistics & numerical data; D008103:Liver Cirrhosis / Q000191:economics* / Q000453:epidemiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012307:Risk Factors